-
The Risks of Innovation in Health Care.
February 18, 2015 Editor Comments Off on The Risks of Innovation in Health Care.
Related Articles The Risks of Innovation in Health Care.
J Am Coll Radiol. 2015 Feb 14;
Authors: Enzmann DR
Abstract
Innovation in health care creates risks that are unevenly distributed. An evolutionary analogy using species to represent business models helps categorize innovation experiments and their risks. This classification reveals two qualitative categories: early and late diversification experiments. Early diversification has prolific innovations with high risk because they encounter a “decimation” stage, during which most experiments disappear. Participants face high risk. The few decimation survivors can be sustaining or disruptive according to Christensen’s criteria. Survivors enter late diversification, during which they again expand, but within a design range limited to variations of the previous surviving designs. Late diversifications carry lower risk. The exception is when disruptive survivors “diversify,” which amplifies their disruption. Health care and radiology will experience both early and late diversifications, often simultaneously. Although oversimplifying Christensen’s concepts, early diversifications are likely to deliver disruptive innovation, whereas late diversifications tend to produce sustaining innovations. Current health care consolidation is a manifestation of late diversification. Early diversifications will appear outside traditional care models and physical health care sites, as well as with new science such as molecular diagnostics. They warrant attention because decimation survivors will present both disruptive and sustaining opportunities to radiology. Radiology must participate in late diversification by incorporating sustaining innovations to its value chain. Given the likelihood of disruptive survivors, radiology should seriously consider disrupting itself rather than waiting for others to do so. Disruption entails significant modifications of its value chain, hence, its business model, for which lessons may become available from the pharmaceutical industry’s current simultaneous experience with early and late diversifications.
PMID: 25686642 [PubMed – as supplied by publisher]
Related Posts
The power of disruptive technological innovation: Transcatheter aortic valve implantation.
Disrupting health care with Google Glass
The dynamics of resource-based economic development: evidence from Australia and Norway
Disrupting the old order of imaging.
Building a culture of innovation by maximizing the role of the RN.
- Five Ways to Innovate Faster
Categories: PubMed
Crowdfunding 2.0: the next-generation philanthropy: A new approach for philanthropists and citizens to co-fund disruptive innovation in global health. Co-Creation in Government
Subscribe to our stories
Recent Posts
- SL Crowd Green Solutions September 21, 2020
- Digital transformation in the banking sector: surveys exploration and analytics August 3, 2020
- Why Let Others Disrupt You? Take the Smart Self-Disruption Journey! August 3, 2020
- 5 Tips for Crowdfunding During the Pandemic August 3, 2020
- innovation + africa; +639 new citations August 3, 2020
Categories
Archives
Popular Post-All time
- A review on biomass-based... 0.9k views
- Can blockchain disrupt ge... 672 views
- Prize-winning projects pr... 646 views
- Apply Now: $500,000 for Y... 602 views
- Test Your Value Propositi... 523 views
Comments are currently closed.